Literature DB >> 25632192

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

Christopher Leung1, Sern Wei Yeoh1, Desmond Patrick1, Shara Ket1, Kaye Marion1, Paul Gow1, Peter W Angus1.   

Abstract

AIM: To determine characteristics and prognostic predictors of patients with hepatocellular carcinoma (HCC) in association with non-alcoholic fatty liver disease (NAFLD).
METHODS: We reviewed the records of all patients with NAFLD associated HCC between 2000 and 2012. Data collected included demographics; histology; presence or absence of cirrhosis, size and number of HCC, alpha-fetoprotein, body mass index (BMI), and the presence of diabetes, hypertension, or dyslipidaemia.
RESULTS: Fifty-four patients with NAFLD associated HCC were identified. Mean age was 64 years with 87% male. Fifteen percent (8/54) were not cirrhotic. 11%, 24% and 50% had a BMI of <25 kg/m2, 25-29 kg/m2 and ≥30 kg/m2 respectively. Fifty-nine percent were diabetic, 44% hypertensive and 26% hyperlipidaemic. Thirty-four percent of the patients had ≤1 of these risk factors. Non-cirrhotics had a significantly larger mean tumour diameter at diagnosis than cirrhotics (P=0.041). Multivariate analysis did not identify any other patient characteristics that predicted the size or number of HCC.
CONCLUSION: HCC can develop in NAFLD without cirrhosis. At diagnosis such tumours are larger than those in cirrhotics, conferring a poorer prognosis.

Entities:  

Keywords:  Cryptogenic cirrhosis; Hepatocellular carcinoma; Metabolic syndrome; Non-alcoholic fatty liver disease; Screening

Mesh:

Year:  2015        PMID: 25632192      PMCID: PMC4306163          DOI: 10.3748/wjg.v21.i4.1189

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

4.  Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk.

Authors:  Chia-Chi Wang; Tai-Chung Tseng; Tsung-Cheng Hsieh; Ching-Sheng Hsu; Pin-Chao Wang; Hans Hsienhong Lin; Jia-Horng Kao
Journal:  Kaohsiung J Med Sci       Date:  2012-01-17       Impact factor: 2.744

5.  Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.

Authors:  Heather M Patton; Katherine Yates; Aynur Unalp-Arida; Cynthia A Behling; Terry T-K Huang; Philip Rosenthal; Arun J Sanyal; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Am J Gastroenterol       Date:  2010-04-06       Impact factor: 10.864

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.

Authors:  Yasuji Arase; Mariko Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Yusuke Kawamura; Norio Akuta; Norihiro Imai; Masahiro Kobayashi; Hitomi Sezaki; Naoki Matsumoto; Satoshi Saito; Tetsuya Hosaka; Kenji Ikeda; Hiromitsu Kumada; Yuki Ohmoto; Kazuhisa Amakawa; Shiun Dong Hsieh; Kyoko Ogawa; Maho Tanabe; Hiroshi Tsuji; Tetsuro Kobayashi
Journal:  Hepatol Res       Date:  2011-12-19       Impact factor: 4.288

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  36 in total

Review 1.  Is That Possible to Stop or Cease the NASH to Turn into HCC?

Authors:  Ahmet Uygun
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 3.  Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Stephanie Klein; Jean-François Dufour
Journal:  Hepat Oncol       Date:  2017-10-30

Review 4.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

5.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: new insights on presentation and natural history.

Authors:  Danny Issa; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

6.  Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype.

Authors:  Priscila B de Campos; Claudia P Oliveira; José T Stefano; Sebastião N Martins-Filho; Aline L Chagas; Paulo Herman; Luiz C D'Albuquerque; Mário R Alvares-da-Silva; Adhemar Longatto-Filho; Flair J Carrilho; Venancio A F Alves
Journal:  Histol Histopathol       Date:  2019-12-20       Impact factor: 2.303

7.  Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses.

Authors:  Hae-Ki Min; Hitoshi Maruyama; Byoung Kuk Jang; Masahiko Shimada; Faridoddin Mirshahi; Shunlin Ren; Youngman Oh; Puneet Puri; Arun J Sanyal
Journal:  FASEB J       Date:  2016-08-23       Impact factor: 5.191

Review 8.  Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.

Authors:  James Philip G Esteban; Amon Asgharpour
Journal:  Transl Gastroenterol Hepatol       Date:  2022-07-25

9.  Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.

Authors:  Amir Sultan; Chimaobi M Anugwom; Zerihun Wondifraw; Grace A Braimoh; Abate Bane; Jose D Debes
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-08-09       Impact factor: 3.869

10.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.

Authors:  Bashar Mohamad; Vaishal Shah; Mykola Onyshchenko; Mohammed Elshamy; Federico Aucejo; Rocio Lopez; Ibrahim A Hanouneh; Razan Alhaddad; Naim Alkhouri
Journal:  Hepatol Int       Date:  2015-11-11       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.